Steve McGaraughty currently serves as the Head of Electrophysiology in the Neuroscience Department, AbbVie, IL, USA. He received his Ph.D. degree in 1993 from the University of Waterloo in Waterloo, ON, Canada, and subsequently did postdoctoral work at McGill University, Montreal, QC, Canada, as well as at the Oregon Health Science University, Portland, OR, USA. He has been at Abbott Laboratories since 1998 and has led preclinical groups that conduct behavioral, functional MRI, and electrophysiological research to advance the identification and development of new compounds for the treatment of pathological pain. His group also conducts human sensory testing in early clinical evaluation of novel analgesics. His published research includes the mechanistic examination of several receptor targets, including purines (P2X3, P2X7, and AKIs), TRPV1, TRPA1, CB2, Cav2.2, KCNQ2/3, H3, Nav1.8, opioid, mGluR1, and NNR in animal models of pathological pain. McGaraughty was inducted into Abbott’s Volwiler Society in 2006, a membership that is reserved for Abbott’s most distinguished scientists and recognizes their achievements in research and development.
Biography Updated on 27 August 2014